Icon: FY13 bolstered by M&A strategy, bolt-on acqusitions to continue

By Dan Stanton

- Last updated on GMT

Related tags Investment

Strong year for Icon; More acquisitions to come
Strong year for Icon; More acquisitions to come
Icon says it intends to continue its M&A strategy focusing on capabilities, geographies and technologies as it reports a robust 2013.

For the full year 2013, Icon’s revenue grew 20% to $1.34bn (€970m). Operating income before restructuring and other items was $130.2m compared to $73.7m last year - an increase of 77%. Operating margin was 9.7% of revenue compared with 6.6% of revenue in 2012

One factor CEO Ciaran Murray attributed to the strong performance was Icon’s procurement policy which since 2008 has seen the firm invest around $300m on eleven acquisitions.

He told stakeholders during a conference call to discuss results last week the benefit of those investments was paying off but due to the changing nature of the CRO market the firm was looking for continuous bolt-on acquisitions.

“We've identified a number of areas where we still need to build up our capability,”​ Murray said (according to the call transcript, courtesy of Seeking Alpha​), whilst the firm also looks to bolster “certain specific capabilities and skills as customers descale in areas of medical and scientific capability.”

There is continued opportunity in the CRO market, he told stakeholder, “as the biopharma industry continues to outsource more, look for more productivity in its R&D offering, [and] as it develops more partnerships and partnerships of a more strategic nature.”

He continued: “In order to play in that market, we took the decision a number of years ago that we had to invest in having the scale and the range of services and the technology and innovation that will help our customers do that.”

Last year Icon bought the clinical trials service business of Cross County Healthcare​, including Akos and Clinforce, and in 2012 the firm added Beijing-based clinical trials firm BeijingWits​, whilst purchase of PriceSpective​ and late-phase firm Oxford​ have also boosted the company’s capabilities.  

As for future deals, Murray told investors that though they will not be large or transformational “they'll be meatier, but they'll be targeted bolt-on style acquisitions - they won't be large or transformational.

“We very much work on the structure of looking to add targeted capabilities and to manage integration risk,”​ he continued, adding he expected two or three investments to be targeted over the next year.

Geography and Technology

According to Icon’s balance sheet, net cash stood at $321m at the end of December 2013, considerably higher than the $190m at the end of 2012.

As well as bolt-on capabilities, Icon is looking to geographic and regional capabilities in order to keep up with market movements. “A few years ago, it was Eastern Europe,” Murray said.  We invested there mostly organically.”

“In Asia, we did a combination of organic and M&A, and we continue to look in Asia and in another developing new regions at what we need.”

But the area that is constantly changing, Murray said, was technology and the firm has “an agenda there to drive innovation and the deployment of technology,” ​in order to speed up and improve the quality of development. “So wherever technology takes us in the big data agenda in that field, we'll be looking in that sector,”​ he said.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more